Home ›
NPI 1306839378
NPI deactivated
1306839378
1306839378 was paid $72K by Medicaid between Feb 2019 and Dec 2019, across 13 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 74% of everything it billed.
33Billing provider info1306839378
33aNPI1306839378
33bProvider type—
28Total paid$72K
24GClaims2,522
24DCodes billed13
24AFirst – last monthFeb 2019 – Dec 2019
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 2,522 | $72K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 74% | 1,092 | 919 | $54K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 341 | 318 | $10K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.2% | 46 | 46 | $3K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.9% | 45 | 45 | $2K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.6% | 33 | 33 | $2K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.0% | 56 | 49 | $1K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 189 | 188 | $10.00 |
| G8711 | Prescribed antibiotic on or within 3 days after the episode date | 0% | 151 | 136 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 199 | 195 | $0.00 |
| 90461 | 0% | 62 | 61 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 224 | 204 | $0.00 |
| 90670 | 0% | 24 | 24 | $0.00 |
1 more codes
| 80305 | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.